1. Different doses of methimazole treatment of children and adolescents with graves’ disease: a clinical study based on 161 cases of outpatients
- Author
-
Peng Li, Wei Wang, Meiqin Yan, Xianhui Zhang, Jie Pan, and Lina Gong
- Subjects
Children ,Adolescents ,Graves’ Disease ,Methimazole ,Adverse effects ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Objective This study aimed to evaluate the association between the initial dose of MMI and the clinical course, as well as adverse effects on young people with GD. Methods One hundred and sixty-one children and adolescents with newly diagnosed GD were enrolled for this study and categorized into four groups based on initial serum-free T3 and T4 levels and daily MMI doses: Group A (mild, 0.3–0.5 mg/kg/day, n = 78), Group B (moderate, 0.6–0.8 mg/kg/day, n = 37), Group C (severe, 0.6–0.8 mg/kg/day, n = 24), and Group D (severe, 0.8-1.0 mg/kg/day, n = 22). The thyroid function, blood cell analysis and liver function were examined before treatment and at 4, 8 and 12 weeks after treatment. Outcome of long-term follow-up were also observed. Results After 12 weeks of treatment, 91.0% of the patients in group A and 90.9% of the patients in group D recovered to normalization of FT3, which was slightly higher than the other two groups; 70.8% of the patients in group C recovered to normalization of FT4, which was slightly lower than that in the other three groups. The incidence of minor adverse effects was 12.8% in group A, 13.5% in group B, 16.7% in group C and 40.9% in group D (P
- Published
- 2023
- Full Text
- View/download PDF